Treating iron overload in patients with non-transfusion-dependent thalassemia

被引:67
|
作者
Taher, Ali T. [1 ]
Viprakasit, Vip [2 ,3 ]
Musallam, Khaled M. [1 ,4 ]
Cappellini, M. Domenica [4 ]
机构
[1] Amer Univ Beirut, Med Ctr, Dept Internal Med, Beirut, Lebanon
[2] Mahidol Univ, Siriraj Hosp, Fac Med, Dept Pediat, Bangkok 10700, Thailand
[3] Mahidol Univ, Siriraj Hosp, Fac Med, Siriraj Thalassemia Ctr, Bangkok 10700, Thailand
[4] Univ Milan, Ca Granda Fdn IRCCS, Dept Med & Med Special, Milan, Italy
关键词
MAGNETIC-RESONANCE EVALUATION; BETA-THALASSEMIA; HEPATIC IRON; CHELATION-THERAPY; SERUM FERRITIN; HEPATOCELLULAR-CARCINOMA; SPLENECTOMIZED ADULTS; PEPTIDE HEPCIDIN; H DISEASE; LIVER;
D O I
10.1002/ajh.23405
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Despite receiving no or only occasional blood transfusions, patients with non-transfusion-dependent thalassemia (NTDT) have increased intestinal iron absorption and can accumulate iron to levels comparable with transfusion-dependent patients. This iron accumulation occurs more slowly in NTDT patients compared to transfusion-dependent thalassemia patients, and complications do not arise until later in life. It remains crucial for these patients' health to monitor and appropriately treat their iron burden. Based on recent data, including a randomized clinical trial on iron chelation in NTDT, a simple iron chelation treatment algorithm is presented to assist physicians with monitoring iron burden and initiating chelation therapy in this group of patients. Am. J. Hematol. 88: 409-415, 2013. (C) 2013 Wiley Periodicals, Inc.
引用
收藏
页码:409 / 415
页数:7
相关论文
共 50 条
  • [21] Non-Transfusion-Dependent Thalassemia: A Panoramic Review
    Shash, Hwazen
    MEDICINA-LITHUANIA, 2022, 58 (10):
  • [22] Non-transfusion-dependent thalassemia (NTDT) - therapy
    Dickerhoff, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 121 - 122
  • [23] The definition and epidemiology of non-transfusion-dependent thalassemia
    Weatherall, David J.
    BLOOD REVIEWS, 2012, 26 : S3 - S6
  • [24] Deferasirox: A Review of Its Use for Chronic Iron Overload in Patients with Non-Transfusion-Dependent Thalassaemia
    Matt Shirley
    Greg L. Plosker
    Drugs, 2014, 74 : 1017 - 1027
  • [25] Deferasirox: A Review of Its Use for Chronic Iron Overload in Patients with Non-Transfusion-Dependent Thalassaemia
    Shirley, Matt
    Plosker, Greg L.
    DRUGS, 2014, 74 (09) : 1017 - 1027
  • [26] Profile of deferasirox for the treatment of patients with non-transfusion-dependent thalassemia syndromes
    Ricchi, Paolo
    Marsella, Maria
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 6475 - 6482
  • [27] Effect of Iron Chelation Therapy on Glucose Metabolism in Non-Transfusion-Dependent Thalassemia
    Chuansumrit, Ampaiwan
    Pengpis, Pimprae
    Mahachoklertwattana, Pat
    Sirachainan, Nongnuch
    Poomthavorn, Preamrudee
    Sungkarat, Witaya
    Kadegasem, Praguywan
    Khlairit, Patcharin
    Wongwerawattanakoon, Pakawan
    BLOOD, 2015, 126 (23)
  • [28] Management of Non-Transfusion-Dependent Thalassemia: A Practical Guide
    Taher, Ali T.
    Cappellini, Maria Domenica
    DRUGS, 2014, 74 (15) : 1719 - 1729
  • [29] Premature Atherosclerosis in Non-Transfusion-Dependent β-Thalassemia Intermedia
    Hahalis, George
    Kalogeropoulos, Andreas
    Terzis, George
    Tselepis, Alexandros D.
    Kourakli, Alexandra
    Mylona, Panagiota
    Grapsas, Nikos
    Alexopoulos, Dimitrios
    CARDIOLOGY, 2011, 118 (03) : 159 - 163
  • [30] Iron overload in transfusion-dependent thalassemia
    Saliba, Antoine
    Taher, Ali
    HEMATOLOGY, 2015, 20 (05) : 311 - 312